A phase 2 study of combination therapy with gemcitabine and candesartan in patients with advanced or recurrent pancreatic cancer
Phase 2
- Conditions
- pancreatic cancer
- Registration Number
- JPRN-UMIN000005580
- Lead Sponsor
- niversity of Tokyo, Department of Gastroenterology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 33
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with systolic blood pressure < 100mmHg 2) Patients with an active concomitant infection 3) Patients with digestive ulcer or gastrointestinal bleeding 4) Patients with severe heart or renal disease 5) Patients with an active pulmonary fibrosis or interstitial pneumonia 6) Patients with a previous history of a severe drug hypersensitivity 7) Patients with an active concomitant malignancy 8) Pregnant, lactating female and patients of reproductive potential who did not use effective contraception 9) Patients with uncontrollable massive pleural effusion or massive ascites 10) Inappropriate patients for entry on this study in the judgement of the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time to progression
- Secondary Outcome Measures
Name Time Method Response rate, disease control rate, overall survival, toxicity